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Abstract
The tumor microenvironment mediates induction of the immunosuppressive programmed death-1
(PD-1) pathway, targeted interventions against which can help restore antitumor immunity. To
gain insight into these responses, we studied the interaction between PD-1 expressed on T cells
and its ligands (PD-1:PD-L1, PD-1:PD-L2, and PD-L1:B7.1) expressed on other cells in the tumor
microenvironment, using a syngeneic orthotopic mouse model of epithelial ovarian cancer (ID8).
Exhaustion of tumor-infiltrating lymphocytes (TILs) correlated with expression of PD-1 ligands
by tumor cells and tumor-derived myeloid cells, including macrophages (TAM), dendritic cells
(DC) and myeloid-derived suppressor cells (MDSC). When combined with GVAX or FVAX
vaccination (consisting of irradiated ID8 cells expressing GM-CSF or FLT3 ligand) and co-
stimulation by agonistic α4-1BB or TLR 9 ligand, antibody mediated blockade of PD-1 or PD-L1
triggered rejection of ID8 tumors in 75% of tumor-bearing mice. This therapeutic effect was
associated with increased proliferation and function of tumor antigen-specific effector CD8+ T
cells, inhibition of suppressive T regulatory cells (Tregs) and MDSC, upregulation of effector T
cell signaling molecules and generation of T memory precursor cells. Overall, PD-1/PD-L1
blockade enhanced the amplitude of tumor immunity by reprogramming suppressive and
stimulatory signals that yielded more powerful cancer control.
Introduction
At the time of diagnosis, over 75% of patients with ovarian cancer present with advanced
stage III or IV disease (1–2). Despite appropriate surgery and receiving highly effective
first-line chemotherapy, ~70% of patients with advanced-stage disease who achieve
remission eventually relapse (1–2). Thus, there is an immediate need for therapeutic targets
for treating ovarian cancer (3). Our group and others have reported that tumor-infiltrating T
lymphocytes (TILs) with anti-tumor potential exist in cancer patients (4–7). Studies in a
primary co-culture system showed that TILs from many ovarian cancer patients secrete low
to intermediate levels of IFN-γ and limited proliferation in response to cognate peptides
(unpublished observation). The programmed cell death 1 (PD-1) is an inhibitory surface
receptor expressed by T cells, B cells, natural killer T cells, monocytes, and DCs, but not by
resting T cells. PD-1 binds two ligands, programmed cell death ligand 1 (PD-L1) and PD-
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L2, also called B7-H1 and B7-DC, respectively (8–9). Tumors can employ the PD-1
inhibitory pathway to silence the immune system (8). The expression of PD-L1 in tumors is
inversely correlated with survival of patients (10–11). This indicates that although anti-
tumor immunity is elicited against ovarian cancer, it is counterbalanced by
immunosuppressive factors.
In ovarian tumors, myeloid cells are one of the major determinants of immune suppression.
These include tumor-associated macrophages (TAMs), immature/tolerogenic DCs, and
myeloid-derived suppressor cells (MDSCs) (12–21). In addition, CD4+CD25+Foxp3+ T
regulatory cells (Tregs) play a critical role in the control of anti-tumor immune responses,
relying on PD-1, PD-L1 or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) to
perform these functions (22–27). Most studies describe mechanisms for the accumulation of
these immunosuppresive myeloid cells or Tregs. In this study, we demonstrate a cross-
regulation among these cell types using the ID8 syngeneic mouse model of epithelial
ovarian cancer. We provide evidence that T cell dysfunction can be reversed by targeting the
PD-1 pathway simultaneously in all these cell types. We found that expansion of ovarian
antigen-specific CD8+ TILs was dependent on the amount of PD-L1 signaling by tumor
cells, tumor-derived myeloid cells and Tregs. Furthermore, combining PD-1 blockade with a
single dose of GVAX or FVAX vaccination resulted in enhanced clonal expansion of
antigen-specific CD8+ T cells and tumor control. Finally, we observed a further boost of
CD8+ T cell function when PD-L1 blockade was combined with both vaccination and
α4-1BB co-stimulation. Overall, our study shows that αPD-L1 blockade therapy greatly
synergizes with other immunotherapy modalities.
Methods
Mice and tumor lines
All experiments were performed using protocols approved by the University of
Pennsylvania Laboratory Animal Resources (ULAR) policies. A mouse ovarian epithelial
papillary serous adenocarcinoma cell line (ID8) was obtained from Dr. K. F. Roby,
University of Kansas Medical Center (28). Development of ID8 cells expressing murine
GM-CSF (ID8-GVAX) or Flt3-ligand (ID8-FVAX) was based on methods described
previously (29).
Blocking and agonistic antibodies
Rat anti-mouse PD-1 (29F.1A12, at IgG2a, k), PD-L1 (10F.9G2, rat IgG2b, k), PD-L2 (3.2,
mouse IgG1), and isotype control antibodies were used (7). The rat anti-mouse 4-1BB
antibody from BioXcell was also used.
Tumor experiments
C57BL6 mice (n=12) were given an intraperitoneal (i.p) injection containing 5 × 106 ID8
cells. Two hundred micrograms of rat α-mouse PD-1, -PD-L1, -PD-L2 antibodies, 100 µg of
α-CTLA-4 (clone 9D9) or isotype control antibodies were administered i.p. 4 weeks after
tumor inoculation 5 times on alternate days. For co-stimulation 200 µg of α4-1BB antibody
(BioXcell) was given once along with first aforementioned dose of blocking antibodies. In
vaccination experiments, 106 irradiated (150Gy) gene-modified ID8-GVAX or ID8-FVAX
cells were given by i.p. once, 3 weeks after tumor inoculation. Mice were monitored by their
weight gain twice a week. Mice weighing >35 gm as a result of tumor growth and/or ascites
fluid accumulation were euthanized.
Methods are detailed in the supplementary section.
Duraiswamy et al. Page 2














Lack of T cell infiltration in ovarian tumors is acquired
We have previously reported that, at the steady state, established ID8 tumors are poorly
infiltrated by T cells (33) and are thus considered intrinsically non-immunogenic, mimicking
many human ovarian cancers lacking TILs (6). In this orthotopic model of ovarian cancer,
gross metastatic i.p. nodules appear at approximately 28 days, and tumor and ascites rapidly
accumulate leading to 100% death at 55–60 days (Fig. 1a. We investigated the changes in
the frequency of TILs in ovarian tumors, ascites, and spleens of mice from early (~28 days)
to late times of tumor growth (~52 days). Interestingly, CD3+ (CD8+ and CD4+) T cells
infiltrating during the early tumors were almost completely absent in advanced tumors (Fig.
1b).
Interestingly, a high percent of T cells in advanced tumors were Tregs (34), while there were
no detectable CD8+ T cells left and the depletion of T cells was restricted to tumors. Parallel
to the observed disappearance of CD3+ TILs and the increase in Treg cells, we found a
significant increase in MDSCs (CD11b+Gr-1+, p=0.024) (Fig. 1b; Supplementary Fig. 1)
and TAMs (CD11b+F4/80+, p=0.048) in tumors, but no significant changes in CD11chi DCs
(p=0.10) (not shown). Thus, lack of immunogenicity in established ID8 tumors appears to be
acquired rather than intrinsic.
PD-1 ligands are present in the microenvironment of ovarian tumors
Previous immunohistochemical studies have reported upregulation of PD-L1 in human
ovarian cancers (10). Here we observed high levels of PD-L1 and moderate levels of PD-L2
on ID8 tumor cells, as well as macrophages, DCs and MDSCs derived from the same tumors
(Fig. 2a–b; Supplementary Fig. 2a). Similarly, myeloid cells derived from ascites showed
moderate expression of high levels of PD-L1 and PD-L2, however, spleens showed only low
level expression of PD-L1, but not PD-L2. Next, we found that PD-1 was expressed by
matched CD8+ T cells in tumor at both early and later stages (Fig. 2c; Supplementary Fig.
2b), but PD-1 expression was not detected in other organs except PD-1dim CD8+ T cells in
the liver at early stages of tumor. Thus T cells specifically upregulate PD-1 in the tumor
microenvironment where they are likely to receive inhibitory signals.
PD-1 or PD-L1, but not PD-L2, blockade therapy cause regression of ovarian tumors
We next tested whether the blockade of PD-1 could reverse the decline of T cell immunity
and promote tumor rejection in mice. We also sought to compare the relative contribution of
PD-L1 versus PD-L2. We inoculated C57BL/6 mice i.p. with ID8 tumor cells and then
administered α-PD-1, α-PD-L1 or α-PD-L2 antibodies starting on day 28 (Fig. 3a left).
Treatment with α-PD-1 or α-PD-L1 antibodies resulted in tumor rejection in 25% (3/12) of
the mice, as indicated by normalized mouse weights after treatment (weight gain is due to
ascites fluid accumulation and is an accurate surrogate of tumor growth in this model), and
long-term survival. On the contrary, α-PD-L2 antibody did not reject tumors. To test
whether PD-1-mediated TIL suppression was active at even earlier stages of tumor
development, we treated mice with α-PD-L1 starting on day 21. PD-L1 blockade resulted in
tumor rejection in 60% (7/12) of the mice (Fig. 3a right). Thus, the PD-1 pathway is highly
relevant, and is active very early in the process of establishment of ovarian tumors.
PD-1 or PD-L1, but not PD-L2, blockade therapy prevent immune decline in the tumor
microenvironment
Next, we tested whether PD-1 blockade was associated with reversal of immune decline in
tumors and enhanced TIL infiltration. We chose the more advanced treatment schedule
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(starting on day 28), as above. A week after completion of the treatment (day ~45), residual
peritoneal tumor deposits were resected and analyzed. The frequency of CD8+ and CD4+ T
cells (as well as total CD45+ leukocytes) was markedly increased following α-PD-1 and α-
PD-L1 administration. Interestingly, in spite of the lack of tumor response, there was an
increase in CD8+ and total CD45+ cells also following α-PD-L2 (Fig. 4a). Importantly,
PD-1 and PD-L1 blockade significantly reduced Tregs and thereby increased the CD8+ to
Treg and CD4+ to Treg cell ratios within the tumor (Fig. 4b). On the contrary, no such
decrease in Tregs was seen after α-PD-L2 treatment, and thus there was no significant
change in the CD8+ or CD4+ to Treg ratios.
We also noticed PD-L1 surface expression on Tregs (Supplementary Fig. 1). To understand
whether PD-1-PD-L1 interactions contribute directly to the inhibitory function of tumor
Tregs, CD4+CD25+ Tregs isolated from ID8 tumors were incubated with responder spleen
CD8+ T cells stimulated by immobilized α-CD3 antibody, in the presence or absence of PD-
L1 blocking antibody. T cell proliferation was assessed by CFSE dilution. Whereas Tregs
suppressed responder cell proliferation, α-PD-L1 attenuated the ability of Tregs to suppress
CD8+ T cell proliferation (Fig. 4c, p<0.05; Supplementary Fig. 3). Thus, PD-L1 blockade
not only reduced the relative frequency of Tregs in ID8 tumors, but also attenuates the
suppressive function of tumor-derived Tregs.
MDSCs were also decreased specifically by PD-L1 blockade, which thereby increased the
ratio of T cells to MDSCs within the tumor (Fig. 4d). MDSCs suppress effector T cells
through the production of arginase-I (40, 44). Interestingly, we detected a significantly lower
number of arginase-I positive MDSC in ID8 tumors after treatment with α-PD-L1 (Fig. 4e).
To assess whether arginase-I is involved in the mechanisms through which PD-L1+ MDSCs
suppress TILs in ID8 tumors, CD11b+ Gr1+ isolated from ID8 tumors were further cultured
with ID8 tumor cell supernatants in the presence or absence of α-PD-L1 antibody. Arginase
catalyzes the conversion of arginine to ornithine and urea in the urea cycle. Arginase activity
was evaluated by measuring the urea concentration in the media. We found that PD-L1
blockade decreased the level and activity of arginase-I (Fig. 4f; p=0.0003). Thus, PD-L1
blockade not only reduced the relative frequency of CD11b+ Gr1+ cells, but also reduced
their suppressive phenotype by reducing arginase-I activity, which appears to be dependent
in part on PD-1-PD-L1 interactions.
The above data indicate that PD-1 or PD-L1 blockade significantly attenuated the number
and function of Tregs and/or MDSC. We thus tested whether the above changes were
associated with activation of CD8+ TILs. We detected significant upregulation of Ki-67 and
intracellular granzyme B, as well increased levels of phosphorylated transcription factors, T-
bet, Eomes and S6 kinase, and Akt, supporting the notion that effective PD-1 blockade
activated function and survival pathways in CD8+ TILs (35–36) (Fig. 4g; Supplementary
Fig. 4).
Vaccination synergizes with PD-1 blockade to prevent immune decline in tumors
We theorized that vaccine administered in combination with PD-1 blockade could enhance
the efficacy of PD-1 blockade in preventing immune decline in tumors. Previous studies
have described a therapeutic efficacy of B16 autologous melanoma tumor vaccines
expressing either granulocyte macrophage colony-stimulating factor (GM-CSF) or FMS like
tyrosine kinase 3 ligand (Flt3-ligand), when combined with the blocking CTLA-4 (29, 37–
40). We transduced ID8 whole tumor cells to express either GM-CSF (ID8-GVAX, Fig. 5a)
or Flt3L (ID8-FVAX, Fig. 5b) and used radiated cells as vaccine in combination with PD-1,
PD-L1, or PD-L2 blockade. Mice received weekly vaccine, starting 3 weeks after tumor
inoculation. A week later, mice were treated with PD-1 blocking antibodies 5 times on
alternate days. Although GVAX alone had no effect on tumor growth or mouse survival,
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addition of GVAX doubled the effect of checkpoint blockade on mouse survival. Fifty
percent of mice that received GVAX plus PD-1 or PD-L1 blockade rejected their tumors,
while antibodies alone resulted in 25% tumor rejection (Fig. 5a left). By contrast, α-PD-L2
did not show any positive interaction with vaccination. Similar results were obtained with
FVAX (Fig. 5b left). Interestingly, the positive interaction between vaccine and checkpoint
blockade required full development of the vaccine effect, and this was achieved by
increasing the time interval between vaccination and checkpoint blockade to one week (data
not shown).
Co-stimulatory signals further augment the combination of vaccine plus PD-L1 blockade
The above results indicate that PD-1 or PD-L1 blockade can prevent immune decline in
tumors and that additional of vaccine further enhances this effect. Next we hypothesized that
adding a costimulatory signal, 4-1BB (CD137), a tumor necrosis factor receptor gene family
member (41–45), could further boost TILs and enhance the effects of checkpoint blockade
and vaccination. Mice were vaccinated with GVAX or FVAX starting 3 weeks after tumor
inoculation, and a week later, we administered 5 doses of αPD-L1 on alternate days plus a
single dose of α4-1BB (200 µg) antibody with the first dose of αPD-L1 (Fig. 5a right).
Administration of the α4-1BB antibody alone had no impact on tumor growth or survival.
Furthermore, addition of α4-1BB antibody to PD-L1 blockade had moderate impact on
survival (Fig. 5a right). Remarkably, 75% of mice receiving GVAX followed by αPD-L1
plus α4-1BB antibodies rejected their tumors. Similar results were obtained with FVAX
(Fig. 5b right).
In tumors, costimulatory signals could be provided by properly activated antigen-presenting
cells, which express the 4-1BB ligand as well as other important costimulatory ligands.
Hypothesizing that similar therapeutic benefit as above could be obtained through T cell
costimulation by TLR-activated APCs, we used an agonistic murine TLR9 ligand, CpG
1668 (46). Mice were treated with 5 doses of CpG 1668 i.p. (5 µg/mouse) in combination
with αPD-L1 antibody (Supplementary Fig. 5). Similar to α4-1BB, we found significant
therapeutic benefit by adding CpG. Importantly, the effect from this combination was seen
only when CpG was given in combination with αPD-L1 antibody but not if CpG was given
earlier, in combination with the vaccine, indicating that CpG did not contribute at enhancing
T cell priming. Thus, the therapeutic PD-L1 blockade has the potential to induce significant
tumor rejection, which can be maximized if PD-L1 blockade is preceded by tumor
vaccination, and accompanied by costimulation.
Combination therapy reprograms the tumor immune microenvironment
We next asked what were the changes in the tumor microenvironment induced by the
ineffective vaccines GVAX and FVAX. Interestingly, vaccine alone increased significantly
the frequency of TILs, especially CD8+ cells (p<0.01) (Fig. 5a and Supplementary Fig. 7a).
Because vaccines proved ineffective, we asked whether this was associated with an increase
in immunosuppressive populations. Importantly, we noticed that both GVAX and FVAX
failed to reduce the frequency of Tregs in tumors. Moreover, GVAX increased the frequency
of the MDSC population in tumor leukocytes (Fig. 6c). On the other hand, FVAX increased
the frequency of plasmacytoid DC (pDCs) levels in tumors (Supplementary Fig. 6), which
have been shown to have immunosuppressive properties (47). Thus, vaccine alone increased
TILs but also immunosuppressive cells.
Mice treated with GVAX or FVAX plus αPD-L1 showed significantly increased infiltration
of total inflammatory CD45+ cells and T cells in tumors compared to mice treated with
αPD-L1 (p<0.01) or vaccine (p<0.001) alone. Among them, CD8+ T cells were more
abundant than CD4+ T cells (Fig. 6a and Supplementary Fig. 7a). When PD-L1 blockade
Duraiswamy et al. Page 5













was combined with GVAX or FVAX, there was a moderate reduction in Treg as well as
MDSC levels in the tumor (Figs. 6b&6c; and Supplementary Figs. 7b&7c). The addition of
α4-1BB to αPD-L1 increased significantly TILs relative to each agent alone, both CD8+ and
CD4+. In addition, it markedly reduced Treg cells relative to each agent alone.
Consequently, the combination of α4-1BB plus αPD-L1 resulted in a marked increase in the
CD8/Treg and CD4/Treg ratios, superior than each antibody alone. The combination of
αPD-L1 and α4-1BB with GVAX or FVAX yielded the highest frequency in TILs, both
CD8+ and CD4+. Furthermore, the addition of vaccine did not increase Tregs when αPD-L1
and α4-1BB were combined with GVAX or FVAX, thus resulting in the highest CD8/Treg
and CD4/Treg ratios seen in this study. The triple combination also yielded the highest
frequency of Ki67+ CD8+ T cells compared to that seen with the other combinations (Figs.
6d and Supplementary Fig. 7d). Combination treatment (either GVAX or FVAX plus
α4-1BB and αPD-L1) also increased granzyme B expression, suggesting an enhancement in
cytolytic potential of effector T cells (Figs. 6d and Supplementary Fig. 7d). Increased
phosphorylation of T-bet and Eomes was induced by αPD-L1 antibody alone, and addition
of α4-1BB to αPD-L1 produced only moderate further increases (Fig. 6e and 7e). Thus, the
PD-L1 blockade induced TIL activation, and the combination of GVAX (or FVAX) and
α4-1BB treatment resulted in a further stimulation of the proliferative and cytolytic
capability of TILs. Taken together, these changes could result in a more permissive
environment for immune-mediated tumor rejection.
Combination therapy results in maximal stimulation of tumor-reactive CD8+ TILs
Given the significant changes in the tumor microenvironment, we next tested whether the
functional capacity of tumor-reactive CD8+ TILs was increased following combination
therapy. Tumors from the various treatment groups were freshly dissociated enzymatically,
and total leukocytes isolated from these tumors were seeded in primary mixed co-cultures
and stimulated with Kb-restricted peptides of folate receptor-α or mesothelin, two known
ovarian tumor antigens expressed by ID8 cells. TIL cultures derived from mice treated with
GVAX or FVAX showed minimally increased IFN-γ+ and TNF-α+ CD8+ TIL when
stimulated with the FR-α (SSGHNECPV) and mesothelin (LSIFKHKL and LIWIPALL)
peptides (Fig. 7a & b; and Supplementary Fig. 8). TIL cultures derived from mice treated
with αPD-L1 alone showed modestly increased IFN-γ+ and TNF-α+ CD8+ TIL when
stimulated with the peptides. TIL cultures derived from mice treated with GVAX (or
FVAX) plus αPD-L1 (not shown) or α4-1BB showed further increased IFN-γ+ and TNF-α+
CD8+ TIL when stimulated with the peptides. However, when mice were treated with αPD-
L1 combined with GVAX (or FVAX) and α4-1BB, TILs exhibited the highest numbers of
IFN-γ+ and TNF-α+ CD8+ T cells ex vivo (Fig. 7a & b). Importantly, the increase in IFN-γ
production by TILs specific to FR-α and mesothelin peptides appeared to be correlated with
a decrease in tumor load (Figs. 3 & 5). The functional status of CD8+ TILs was corroborated
by testing the phosphorylation status of key transcription factors. Triple combination therapy
showed significant increases in pT-bet and pS6K levels, although only modest increase in
pEomes (Fig. 7c).
Discussion
In this study, we demonstrate a critically important role of the PD-1 pathway in establishing
an immune privilege site in the ovarian cancer microenvironment. Although tumors were
infiltrated by T cells in very early stages of tumor orthotopic inoculation, a progressive
reduction was noted in the frequency of CD8+ cells and the CD8/Treg cell ratio, until very
few TILs were finally found in advanced tumors. Most of these were Tregs. The role of
Tregs in mediating immune suppression and tumor growth has been previously established
in ovarian cancer (24, 34). A parallel increase in MDSC and TAMs completed the picture of
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a well-organized tumor immune suppressive environment. These findings are important in
two ways. First, they indicate that lack of tumor immunogenicity is not intrinsic, but rather
acquired, at least in ID8 ovarian tumors. Second, we found that such progressive
establishment of immune suppression can be reversed by blocking the PD-1 pathway. Thus,
PD-1 besides mediating TIL exhaustion, can facilitate a profound depletion of TILs.
Importantly, this phenomenon was mediated by PD-L1, since PD-L1 blockade produced
similar results, but not PD-L2.
PD-1 blockade restored the immune decline and led to expansion of TILs. An increase in the
number of CD4+ and CD8+ cells was associated with increased CD8/Treg and CD4/Treg
ratios. This was associated with a moderate clinical response, along with molecular evidence
of functional activation of TILs. Reversal of decline was time-sensitive, since PD-1
blockade was more effective in earlier times, when more TILs were present in tumor
microenvironment. Moreover, the therapeutic effect of blocking PD-1/PD-L1 correlated
with increased numbers of polyfunctional ovarian tumor-antigen (mouse folate receptor-α
and mesothelin) specific CD8+ T cells. Our study also provides further insight that tumor
antigen-specific CD8+ T cells upregulate the key effector and memory precursor signaling
molecules (T-bet, Eomesodermin, Akt, and S6 kinase) up on PD-1/PD-L1 blockade. This is
in agreement with recent studies that described inhibition of signaling pathways by PD-1/
PD-L1 mediated T cell exhaustion (48–53).
Given this observation, we theorized that expanding the pool of tumor reactive TILs through
a whole tumor antigen vaccine (GVAX or FVAX) could be beneficial in more advanced
time points of the disease. We found that in fact, although ineffective on its own, vaccine
could double the efficacy of PD-L1 blockade. Importantly, vaccine inefficiency was not due
to its inability to expand tumor reactive TILs. Rather, increase in TILs was accompanied by
a similar (compensatory) increase in Treg and other immunospuppressive populations (such
as MDSC or pDCs). Thus failure of vaccines was due to their failure to reprogram the tumor
microenvironment, which continued to take advantage of homeostatic anti-inflammatory
mechanisms such as Treg, MDSC and/or pDCs. Importantly, PD-L1 blockade again was
able to break these homeostatic mechanisms, to establish tumor rejection. In addition, we
found administration of agonistic 4-1BB stimulation and α-PD-L1 after vaccination
produced maximal expansion of TILs and tumor rejection. We acknowledge that the dose of
4-1BB antibody (200ug) used was high for human translation and that in humans, 4-1BB
agonistic Abs have resulted in liver toxicity (54). However, we believe that our studies still
provide proof of principle for adding costimulation to checkpoint blockade as a beneficial
therapeutic combination. Interestingly, similar benefit was also obtained by administering
CpG, a TLR9 agonist, intraperitoneally.
In this model PD-L1 blockade was very effective while PD-L2 blockade was ineffective.
This effect is likely due to the high expression level of PD-L1 in ID8 tumor cells as well as
tumor-derived myeloid cells. Although αPD-L2 blockade resulted in moderately increased
levels of TIL infiltration (CD45+, CD8+), proliferation (Ki67+CD8+) and signaling
molecules (Eomes, Akt, and pS6 kinase), Treg and MDSC levels were not reduced after
αPD-L2 blockade. In this regard, we previously noticed low level expression of PD-L2 in
other types of tumor models (23). Hence the lack of response to αPD-L2 blockade may be
due to low level expression of PD-L2, lacking sufficient endogenous response upon in vivo
blocking PD-L2. Although our studies provide strong evidence of a role of PD-L1 in the
syngeneic ovarian model, they do not allow us to discern the relative contribution of PD-L1
expressed by tumor cells versus tumor stroma or infiltrating leukocytes. Future studies using
PD-L1 KO mice and bone marrow chimeras will be required to clarify this point. PD-L1
blockade overcame the upregulation of MDSCs and pDCs by GVAX and FVAX,
respectively. Previous studies reported that FVAX was more effective in combination with
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blockade therapy than GVAX (35). Our study used different clones of rat anti-mouse PD-1
(RMP1-30), and rat anti-mouse PD-L1 (10F.9G2) compared to Bioxcell antibodies, αPD-1
(RMP1-14), αPD-L1 (9G2) used in their study which may have accounted for eliminating
the differences previously observed between the two vaccine preparations.
Our findings have important implications in understanding the immunobiology of ovarian
cancer and developing rational therapies. We have previously described the classification of
ovarian cancers in tumors with and tumors without intraepithelial TILs (4). The present
findings suggest that tumors lacing intraepithelial TILs may have a very active PD-L1
mediated suppression, leading to depletion of TILs. This would be in agreement with
observations by Hamanishi et al. reporting that increased expression of PD-L1 (but not PD-
L2) is associated with poor survival in patients with advanced ovarian cancer, similar to the
lack of intraepithelial TILs (10). Our finding of high frequency of Treg cells in tumors
lacking TILs is consistent with an association of Treg cells with poor outcome in human
ovarian cancer (4) and with the observation that in these tumors we found increased
expression of vascular endothelial growth factor (4), which also correlates with Treg cell
preponderance in the tumor microenvironment (34). Based on the present findings, human
ovarian cancer lacking intraepithelial TILs should not lack intrinsic immunogenicity,
consistent with the notion that most advanced ovarian cancers express known tumor-
associated antigens and harbor tons of non-synonymous mutations, which could give rise to
immunogenic epitopes. Rather, powerful immunosuppressive factors would eliminate TILs,
suggesting that reversal of these factors would restore immune recognition and attack. PD-
L1 blockade could be an important step towards reversing such immunosuppressive
environment, but additional maneuvers are likely required to optimize tumor immune attack.
In the present study, addition of a whole tumor antigen vaccine significantly enhanced the
ability of PD-L1 blockade. Importantly, just as in human patients with ovarian cancer treated
with GVAX (38, 55), vaccine alone was ineffective in the mouse, but was quite beneficial in
association with checkpoint blockade. We found that the reason whole tumor vaccines were
ineffective was because they elicited a significant activation of tumor microenvironment
homeostatic mechanisms, with increased MDSC or pDCs and no decrease in Treg cells.
Importantly, PD-L1 blockade abrogated this rebound increase in immunosuppressive cells
and depleted Treg cells, resulting in clinical benefit. Concomitant costimulation, through an
agonistic antibody or CpG, further enhanced this benefit. Whole tumor antigens have been
proposed as better alternatives than molecularly defined vaccines and can be effective in
inducing antitumor immune responses in patients with ovarian cancer (56). The increased
availability of immunomodulatory antibodies could provide a new role for whole tumor
antigen vaccines according to our findings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Accumulation of myeloid and T cell populations in ID8 tumor
(a) Six to 8 weeks-old mice (n=12) were inoculated i.p. with 5 × 106 ID8 tumor cells. The
survival (i) and scheme (ii) are shown. (b) T (CD3+, CD8+, and CD4+) cells, Treg
(CD4+CD25+Foxp3+) cells, and MDSC (CD11b+Gr1+) from tumor, ascites, spleen of ID8
tumor-bearing mice were isolated and counted (using 0.4% trypan blue stain) from 6 mice
during early (4–5 weeks after tumor inoculation) or rest of the 6 mice during advanced (7–8
weeks after tumor inoculation) tumors. All cell subtypes were CD45+ gated. Bars represent
mean ± SEM.
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Figure 2. Expression of PD-L1, PD-L2 and PD-1 in ID8 mice
Mice were inoculated i.p. with 5×106 ID8 tumor cells (n=12), and their tumor, ascites,
spleen, liver, lung and blood were harvested from half of the mice at early and the other half
at advanced tumor. Tumor cells (EpCAM+), macrophages (CD45+CD11B+F4/80+), DCs
(CD45+CD11c+) and MDSCs (CD45+CD11B+Gr1+) were isolated from the tumor, ascites
and spleen. Histograms show PD-L1 (a) and PD-L2 (b) expression by ID-8 tumor cells as
well as macrophages, DCs and MDSCs from tumor, ascites and spleen of ID-8 tumor-
bearing mice. (c) PD-1 expression on CD8+ T cells from tumor, ascites, spleen, blood, liver
and lung of ID-8 tumor-bearing mice. Results are from one of the 3 experiments.
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Figure 3. PD-1 or PD-L1 blockade causes regression of ID8 tumor
Mice were inoculated i.p. with 5 × 106 ID8 tumor cells (n=12). These mice were injected
either therapeutically (starting at 30 days after tumor inoculation) or prophylactically
(starting at 20 days after tumor inoculation) 5 times i.p. with αPD-1 (200ug), αPD-L1
(200ug), or αPD-L2 (200ug) blocking antibodies on alternate days either alone or in
combination as indicated. The scheme and survival of therapeutic (i) and prophylactic
models (ii) are shown. Results are from one of the 3 representative experiments.
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Figure 4. PD-1 or PD-L1 blockade increases immune activation of TILs in ID8 tumor
One week following completion of blockade treatment, the TILs were harvested from
regressing tumors and stained with various markers. Percentages of CD8+ and CD4+ TIL
(CD45+) infiltration of total leucocytes (a) and the ratio of CD8+ T cells to Tregs (b) are
shown in treated versus untreated groups. (c) Blocking PD-1/PD-L1 interaction reduced
Treg-mediated suppression of CD8+ T cells in vitro. CFSE-labeled CD8+ T cells were co-
cultured with syngeneic, αCD3-loaded DCs with or without Tregs and αPD-L1 or αCTLA-4
as indicated. CD8+ T cells and stimulator APCs were obtained from naive B6 mice. Tregs
were obtained from ID8-tumor bearing mice. Treg-mediated suppression of proliferation of
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naïve CD8+ T cells was noticed. Results from one of 3 experiments are shown. (d) The ratio
of CD8+ T cells to MDSCs are shown. (e) CD8+ TILs from αPD-L1 treated mice were
stained with arginase-1 (8C9 clone from Santa Cruz) and analyzed by flow cytometry. The
CD11b+arginase-1+ MDSCs within CD45+ TILs are shown. (f) Tumor-dervived MDSCs
were plated at 1×106/well in 24-well plates and stimulated with equal amount of tumor
supernatants (from ID8 cells). Following stimulation, cells were added with αPD-L1 and
then arginase I was analyzed after 24 h following washing with PBS and lysis buffer. (g)
Percentage of Ki67+ and Granzyme B+ as well as MFI of pT-bet, pEomes, pS6, and pAkt
expression by CD8+ TILs are shown. The results are the sum of three independent
experiments with 8–10 mice per group.
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Figure 5. Synergistic effect of PD-1 blockade, GVAX or FVAX vaccination, and α4-1BB
costimulation on ovarian ID8 tumor rejection
(a) Three weeks after ID8 tumor inoculation, the mice were given i.p with 2 × 106 irradiated
(150Gy) GVAX (top) or FVAX (bottom) once. A week later mice were injected 5 times i.p.
with αPD-1 (200ug), αPD-L1 (200ug), αPD-L2 (200ug) on alternate days or a single dose
200ug of α-4-1BB either alone or in combination as indicated. Results are from one of the 3
experiments.
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Figure 6. Synergistic effect of PD-1 blockade, GVAX vaccination, and α4-1BB costimulation on
immune activation
TILs from regressing tumors of ID8 mice were harvested a week following completion of
treatment and stained for various markers. Percentages of CD8+ and CD4+ TIL (CD45+)
infiltration of total leucocytes are shown in treated versus untreated groups. The ratio of
CD8+ T cells to Tregs and MDSC are also shown. Percentages of Ki67+CD8+ and MFI of
Granzyme B+CD8+ TIL (CD45+) infiltration of total leukocytes are shown in treated versus
untreated groups. Mean intensity of pT-bet, pEomes, and pS6 expression by CD8+ TILs is
shown. Results from one of the 3 experiments are shown. Bars represent mean ± SEM. *P ≤
0.05; **P ≤ 0.01; ***P < 0.001.
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Figure 7. In vivo PD-L1 blockade increases ovarian tumor antigen (FR-α) specific inflammatory
cytokine production by ID8 TILs
(a) Representative data and summary showing percentage of IFN-γ production by CD8+
TILs from treated mice as indicated. Following treatment with GVAX or FVAX and/or in
vivo αPD-L1 and α-4-1BB antibody treatment, the TILs were harvested and stimulated ex
vivo with FR-α peptide for 5 h at 37°C in the presence of brefeldin-A. For intracellular
staining, permeabilized cells were stained for IFN-γ or phosphorylated form of transcription
factors (T-bet, eomes and S6 kinase). (b) A week after completion of treatment, 2 × 105
CD8+ T cells from 5–10 pooled tumor draining mediastinal lymph nodes were re-stimulated
with 1 × 105 FR-α peptide pulsed DCs for 36–48 h. Cytokine (IFN-γ and TNF-α)
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production from culture supernatant was measured following in vitro culture using cytokine
bead array (CBA) kit. (c) Flow cytometry analysis showing percentage of phosphorylated
(p) T-bet, pEomes and pS6K expression by CD8+ TIL from treated mice. All analyses were
performed using CD8+CD45+ TIL from treated mice. N.S. not significant.
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